Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522165 | 0.83 | LIPG (0.39) | LPLLIPGFFAR1F11P4HB | |
| SCHEMBL30639721 | 0.83 | LIPG (0.39) | LPLLIPGFFAR1F11P4HB | |
| SCHEMBL21734208 | 0.82 | LPL (0.38) | LPLLIPGFFAR1F11PTGS2 | |
| SCHEMBL12373176 | 0.82 | LPL (0.44) | LPLLIPGFFAR1F11P2RX7 | |
| SCHEMBL26071363 | 0.80 | LIPG (0.44) | LPLLIPGFFAR1F11P4HB | |
| SCHEMBL26614723 | 0.80 | LIPG (0.36) | LPLLIPGFFAR1F11P4HB | |
| SCHEMBL30639739 | 0.80 | LIPG (0.36) | LPLLIPGFFAR1F11P4HB | |
| SCHEMBL20361743 | 0.78 | LPL (0.35) | LPLLIPGFFAR1F11P4HB | |
| SCHEMBL20361741 | 0.78 | LPL (0.35) | LPLLIPGFFAR1F11P4HB | |
| SCHEMBL29636295 | 0.76 | LIPG (0.38) | LPLLIPGFFAR1F11GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867232-B1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| EP-2867232-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014001377-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | GENENTECH,INC. | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | LPL 4819/4885LIPG 4443/4885HDAC8 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.